Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy - VISION Cohort B

Sep 28, 2026

Uploaded by Mary Man

High-level MET amplification (METamp) drives a small fraction of non-small cell lung cancers, and liquid biopsy can identify these patients for targeted therapy. In VISION trial Cohort B, tepotinib, an oral MET inhibitor, was assessed in 24 enrolled patients with advanced NSCLC and high-level METamp. Despite halting before planned enrollment, tepotinib demonstrated antitumor activity with objective response rate (ORR) 41.7% and median duration of response 14.3 months. Safety showed mainly mild-to-moderate adverse events without new signals, and exploratory biomarkers correlated with outcomes.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages15

Reading Time38 min

AccessFree to download

In brief

Study objective and population

Efficacy outcomes

Safety and adverse events

Exploratory biomarker findings

Article Tepotinib in patients with non-small cell lung cancer with high-level MET ampliﬁcation detected by liquid biopsy: VISION Cohort B Authors Xiuning Le, Luis G. Paz-Ares, Jan Van Meerbeeck, ..., Gordon Otto, Andreas Johne, Paul K. Paik Correspondence [xle1@mdanderson.org](xle1@mdanderson.org) In brief High-level METampliﬁcation (METamp) is a primary driver in 􀀁 1%–2% of non-small cell lung cancers (NSCLCs) . Le et al. report that tepotinib provides antitumor activity in patients with high-level METamp NSCLC in VISION trial Cohort B. Tepotinib is a promising option for these patients, who urgently require new treatments. d High-level MET ampliﬁcation (METamp) is a primary driver in 􀀁 1%–2% of NSCLCs d VISION Cohort B evaluates tepotinib in 24 patients with highlevel METamp NSCLC d Tepotinib shows antitumor activity: ORR is 41.7%, and median DOR is 14.3 months d Safety is manageable, with mostly mild/moderate AEs and no new safety signals Le et al., 2023, Cell Reports Medicine 4, 101280 November 21, 2023 ª 2023 The Authors. [https://doi.org/10.1016/j.xcrm.2023.101280](https://doi.org/10.1016/j.xcrm.2023.101280) ll ll OPEN ACCESS Article Tepotinib in patients with non-small cell lung cancer with high-level METampliﬁcation detected by liquid biopsy: VISION Cohort B Xiuning Le,1,* Luis G. Paz-Ares,2 Jan Van Meerbeeck,3 Santiago Viteri,4,26 Carlos Cabrera Galvez,5 Egbert F. Smit,6,27 Marina Garassino,7 Remi Veillon,8 David Vicente Baz,9 Jose Fuentes Pradera,10 Mara Sereno,11 Toshiyuki Kozuki,12 Young-Chul Kim,13 Seung Soo Yoo,14 Ji-Youn Han,15 Jin-Hyoung Kang,16 Choon-Hee Son,17 Yoon Ji Choi,18 Christopher Stroh,19 Dilafruz Juraeva,20 Helene Vioix,21 Rolf Bruns,22 Gordon Otto,23 Andreas Johne,23,28 and Paul K. Paik24,25 1Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 2Department of Medical Oncology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain 3Department of Thoracic Oncology, Antwerp University Hospital (UZA), 2650 Edegem, Belgium 4Instituto Oncologico Dr. Rosell, Hospital Universitari Dexeus, Grupo QuironSalud, 08028 Barcelona, Spain 5Department of Medical Oncology, Hospital Universitari Sagrat Cor, 08029 Barcelona, Spain 6Department of Thoracic Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands 7Department of Medicine, Section of Hematology/Oncology, Knapp Center for Biomedical Discovery, The University of Chicago, Chicago, IL 1084250, USA 8CHU Bordeaux, Service des Maladies Respiratoires, 33000 Bordeaux, France 9Department of Medical Oncology, Hospital Universitario Virgen Macarena, 41009 Seville, Spain 10Department of Medical Oncology, Hospital Universitario Nuestra Se˜nora de Valme, 41014 Seville, Spain 11Department of Medical Oncology, Hospital Universitario Infanta Soﬁa, San Sebasti´an de los Reyes, 28703 Madrid, Spain 12Department of Respiratory Medicine, NHO Shikoku Cancer Center, Matsuyama City 791-0280, Japan 13Department of Internal Medicine, Chonnam National University Medical School and CNU Hwasun Hospital, Hwasun-Gun 58128, Rep. of Korea 14Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu 41566, Rep. of Korea 15The Center for Lung Cancer, National Cancer Center, Goyang 10408, Rep. of Korea 16Division of Medical Oncology, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul 06591, Rep. of Korea 17Department of Internal Medicine, Dong-A University, 840 Hadan 2-dong, Saha-gu, Busan 604-714, Rep. of Korea 18Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul 02841, Rep. of Korea 19Clinical Biomarkers & Companion Diagnostics, the healthcare business of Merck KGaA, 64293 Darmstadt, Germany 20Oncology Bioinformatics, the healthcare business of Merck KGaA, 64293 Darmstadt, German

FAQs

What is the purpose of VISION Cohort B?

VISION Cohort B evaluates tepotinib in patients with advanced non-small cell lung cancer identified as having high-level MET amplification by liquid biopsy.

What efficacy results were reported for tepotinib?

Tepotinib showed an objective response rate (ORR) of 41.7% and a median duration of response of 14.3 months.

What adverse events were highlighted in the safety results?

Adverse events included edema (any grade 58.3%; grade 3 12.5%) and constipation (any grade 41.7%; grade 3 4.2%).

Sep 28, 2026

Uploaded by Mary Man